𝔖 Bobbio Scriptorium

✦ LIBER ✦

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (‘Iressa’), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in advanced colorectal cancer (ACRC)

✍ Scribed by L. Hammond; J. Figueroa; L. Schwartzberg; L. Ochoa; M. Hidalgo; N. Olivo; G. Schwartz; L. Smith; J. Ochs; E. Rowinsky

Book ID: 117657922
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 346 KB
Volume: 37
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(01)80551-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Preclinical rationale for a combined tre

Preclinical rationale for a combined treatment with irinotecan and the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (Iressa) in irinotecan-refractory human colon cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 157 KB

ZD1839 (‘Iressa’), an orally-active, sel

ZD1839 (‘Iressa’), an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours: preliminary tolerability, efficacy and pharmacokinetic results

✍ G. Giaccone; J.L. Gonzales-Larriba; E.F. Smit; A.T. van Oosterom; M. Martins; G. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 338 KB

Antitumor activity of the epidermal grow

Antitumor activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘lressa’), alone or combined with gemcitabine and vinorelbine platinum-based chemotherapy, in human non-small-cell lung cancer (NSCLC) xenografts

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Pilot trial of ZD1839 (IressaTM), an ora

Pilot trial of ZD1839 (IressaTM), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC)

✍ Laurie, S.A; Miller, V.A; Johnson, D; Ng, K.K; Heelan, R.T; Pizzo, B.A; Perez, W 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 116 KB

Cetuximab (C225, Erbitux) in combination

Cetuximab (C225, Erbitux) in combination with irinotecan, infusional 5-fluorouracil (5-FU) and folinic acid (FA) is safe and active in patients (pts) with metastatic colorectal cancer (CRC) expressing epidermal growth factor-receptor (EGFR). Results of a phase I study

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 306 KB